These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 35677732)

  • 1. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials.
    Selvaraj V; Finn A; Lal A; Khan MS; Dapaah-Afriyie K; Carino GP
    EClinicalMedicine; 2022 Jul; 49():101489. PubMed ID: 35677732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Phase I/II Clinical Trial to evaluate the efficacy of baricitinib to prevent respiratory insufficiency progression in onco-hematological patients affected with COVID19: A structured summary of a study protocol for a randomised controlled trial.
    Moreno-González G; Mussetti A; Albasanz-Puig A; Salvador I; Sureda A; Gudiol C; Salazar R; Marin M; Garcia M; Navarro V; de la Haba Vaca I; Coma E; Sanz-Linares G; Dura X; Fontanals S; Serrano G; Cruz C; Mañez R
    Trials; 2021 Feb; 22(1):116. PubMed ID: 33546739
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis.
    RECOVERY Collaborative Group
    Lancet; 2022 Jul; 400(10349):359-368. PubMed ID: 35908569
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: an exploratory, randomised, placebo-controlled trial.
    Ely EW; Ramanan AV; Kartman CE; de Bono S; Liao R; Piruzeli MLB; Goldman JD; Saraiva JFK; Chakladar S; Marconi VC;
    Lancet Respir Med; 2022 Apr; 10(4):327-336. PubMed ID: 35123660
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Janus kinase inhibitors for the treatment of COVID-19.
    Kramer A; Prinz C; Fichtner F; Fischer AL; Thieme V; Grundeis F; Spagl M; Seeber C; Piechotta V; Metzendorf MI; Golinski M; Moerer O; Stephani C; Mikolajewska A; Kluge S; Stegemann M; Laudi S; Skoetz N
    Cochrane Database Syst Rev; 2022 Jun; 6(6):CD015209. PubMed ID: 35695334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.
    Marconi VC; Ramanan AV; de Bono S; Kartman CE; Krishnan V; Liao R; Piruzeli MLB; Goldman JD; Alatorre-Alexander J; de Cassia Pellegrini R; Estrada V; Som M; Cardoso A; Chakladar S; Crowe B; Reis P; Zhang X; Adams DH; Ely EW;
    Lancet Respir Med; 2021 Dec; 9(12):1407-1418. PubMed ID: 34480861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of the Addition of Baricitinib to Standard of Care Including Tocilizumab and Corticosteroids on Mortality and Safety in Severe COVID-19.
    Masiá M; Padilla S; García JA; García-Abellán J; Navarro A; Guillén L; Telenti G; Mascarell P; Botella Á; Gutiérrez F
    Front Med (Lausanne); 2021; 8():749657. PubMed ID: 34820393
    [No Abstract]   [Full Text] [Related]  

  • 8. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial.
    Wolfe CR; Tomashek KM; Patterson TF; Gomez CA; Marconi VC; Jain MK; Yang OO; Paules CI; Palacios GMR; Grossberg R; Harkins MS; Mularski RA; Erdmann N; Sandkovsky U; Almasri E; Pineda JR; Dretler AW; de Castilla DL; Branche AR; Park PK; Mehta AK; Short WR; McLellan SLF; Kline S; Iovine NM; El Sahly HM; Doernberg SB; Oh MD; Huprikar N; Hohmann E; Kelley CF; Holodniy M; Kim ES; Sweeney DA; Finberg RW; Grimes KA; Maves RC; Ko ER; Engemann JJ; Taylor BS; Ponce PO; Larson L; Melendez DP; Seibert AM; Rouphael NG; Strebe J; Clark JL; Julian KG; de Leon AP; Cardoso A; de Bono S; Atmar RL; Ganesan A; Ferreira JL; Green M; Makowski M; Bonnett T; Beresnev T; Ghazaryan V; Dempsey W; Nayak SU; Dodd LE; Beigel JH; Kalil AC;
    Lancet Respir Med; 2022 Sep; 10(9):888-899. PubMed ID: 35617986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19.
    Kreuzberger N; Hirsch C; Chai KL; Tomlinson E; Khosravi Z; Popp M; Neidhardt M; Piechotta V; Salomon S; Valk SJ; Monsef I; Schmaderer C; Wood EM; So-Osman C; Roberts DJ; McQuilten Z; Estcourt LJ; Skoetz N
    Cochrane Database Syst Rev; 2021 Sep; 9(9):CD013825. PubMed ID: 34473343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trial.
    Garcia-Vicuña R; Abad-Santos F; González-Alvaro I; Ramos-Lima F; Sanz JS
    Trials; 2020 Sep; 21(1):772. PubMed ID: 32907638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (TACTIC-R): a randomised, parallel-arm, open-label, phase 4 trial.
    Hall FC; Cheriyan J; Cope AP; Galloway J; Wilkinson I; Bond S; Norton S; Banham-Hall E; Bayes H; Kostapanos M; Nodale M; Petchey WG; Sheeran T; Underwood J; Jayne DR;
    Lancet Respir Med; 2023 Dec; 11(12):1064-1074. PubMed ID: 37977159
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
    Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
    Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Randomised controlled trial comparing efficacy and safety of high versus low Low-Molecular Weight Heparin dosages in hospitalized patients with severe COVID-19 pneumonia and coagulopathy not requiring invasive mechanical ventilation (COVID-19 HD): a structured summary of a study protocol.
    Marietta M; Vandelli P; Mighali P; Vicini R; Coluccio V; D'Amico R;
    Trials; 2020 Jun; 21(1):574. PubMed ID: 32586394
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Remdesivir for the treatment of COVID-19.
    Ansems K; Grundeis F; Dahms K; Mikolajewska A; Thieme V; Piechotta V; Metzendorf MI; Stegemann M; Benstoem C; Fichtner F
    Cochrane Database Syst Rev; 2021 Aug; 8(8):CD014962. PubMed ID: 34350582
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Colchicine for the treatment of COVID-19.
    Mikolajewska A; Fischer AL; Piechotta V; Mueller A; Metzendorf MI; Becker M; Dorando E; Pacheco RL; Martimbianco ALC; Riera R; Skoetz N; Stegemann M
    Cochrane Database Syst Rev; 2021 Oct; 10(10):CD015045. PubMed ID: 34658014
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Variation in outcome of invasive mechanical ventilation between different countries for patients with severe COVID-19: A systematic review and meta-analysis.
    Elsayed HH; Hassaballa AS; Ahmed TA; Gumaa M; Sharkawy HY; Moharram AA
    PLoS One; 2021; 16(6):e0252760. PubMed ID: 34086779
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tocilizumab versus baricitinib in hospitalized patients with severe COVID-19: an open label, randomized controlled trial.
    Karampitsakos T; Papaioannou O; Tsiri P; Katsaras M; Katsimpris A; Kalogeropoulos AP; Malakounidou E; Zarkadi E; Tsirikos G; Georgiopoulou V; Sotiropoulou V; Koulousousa E; Chourpiliadi C; Matsioulas A; Lagadinou M; Sampsonas F; Akinosoglou K; Marangos M; Tzouvelekis A
    Clin Microbiol Infect; 2023 Mar; 29(3):372-378. PubMed ID: 36273769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multi-arm Trial of Inflammatory Signal Inhibitors (MATIS) for hospitalised patients with mild or moderate COVID-19 pneumonia: a structured summary of a study protocol for a randomised controlled trial.
    Vergis N; Phillips R; Cornelius V; Katsarou A; Youngstein T; Cook L; Willicombe M; Pilay C; Shturova T; Almonte M; Charania A; Turner R; Kon OM; Cooke G; Thursz M; Cherlin S; Wason J; Milojkovic D; Innes AJ; Cooper N
    Trials; 2021 Apr; 22(1):270. PubMed ID: 33845867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Remdesivir for the treatment of COVID-19.
    Grundeis F; Ansems K; Dahms K; Thieme V; Metzendorf MI; Skoetz N; Benstoem C; Mikolajewska A; Griesel M; Fichtner F; Stegemann M
    Cochrane Database Syst Rev; 2023 Jan; 1(1):CD014962. PubMed ID: 36695483
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of baricitinib and tocilizumab in hospitalized patients with COVID-19: A comparison using systematic review and meta-analysis.
    Cherian JJ; Eerike M; Bagepally BS; Das S; Panda S
    Front Pharmacol; 2022; 13():1004308. PubMed ID: 36330085
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.